1044209-74-6

Basic information

• Product Name: C₁₃H₁₂N₂O₃
• Synonyms: C₁₃H₁₂N₂O₃
• CAS NO: 1044209-74-6
• Molecular Weight: 244.25
• Mol File: 1044209-74-6.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: C₁₃H₁₂N₂O₃(CAS DataBase Reference)
• NIST Chemistry Reference: C₁₃H₁₂N₂O₃(1044209-74-6)
• EPA Substance Registry System: C₁₃H₁₂N₂O₃(1044209-74-6)

Safety Data

• Hazardous Substances Data: 1044209-74-6(Hazardous Substances Data)

Upstream product

• 554-84-7 meta-nitrophenol 
• 585-79-5 m-nitrobromobenzene 
• 536-90-3 m-Anisidine 
• 32578-25-9 trifluoromethanesulfonic acid 3-nitrophenyl ester 

Downstream Products

• 600121-10-6 3-methoxyphenyl-(3-amino-phenyl)-amine 

Relevant articles and documents

Design, Synthesis, and Structure-Activity Relationships of Indoline-Based Kelch-like ECH-Associated Protein 1-Nuclear Factor (Erythroid-Derived 2)-Like 2 (Keap1-Nrf2) Protein-Protein Interaction Inhibitors

The Keap1 (Kelch-like ECH-associated protein 1)-Nrf2 (nuclear factor erythroid 2-related factor 2)-ARE (antioxidant response element) pathway is the major defending mechanism against oxidative stresses, and directly disrupting the Keap1-Nrf2 protein-protein interaction (PPI) has been an attractive strategy to target oxidative stress-related diseases, including cardiovascular diseases. Here, we describe the design, synthesis, and structure-activity relationships (SARs) of indoline-based compounds as potent Keap1-Nrf2 PPI inhibitors. Comprehensive SAR analysis and thermodynamics-guided optimization identified 19a as the most potent inhibitor in this series, with an IC50 of 22 nM in a competitive fluorescence polarization assay. Further evaluation indicated the proper drug-like properties of 19a. Compound 19a dose-dependently upregulated genes and protein level of Nrf2 as well as its downstream markers and showed protective effects against lipopolysaccharide-induced injury in both H9c2 cardiac cells and mouse models. Collectively, we reported here a novel indoline-based Keap1-Nrf2 PPI inhibitor as a potential cardioprotective agent.

THERAMUTEIN MODULATORS

This invention relates to agents that are inhibitors or activators of variant forms of endogenous proteins and novel methods of identifying such variants. Of particular interest are inhibitors and activators of endogenous protein variants, encoded by genes which have mutated, which variants often arise or are at least first identified as having arisen following exposure to a chemical agent which is known to be an inhibitor or activator of the corresponding unmutated endogenous protein.